While 2020 did not go as planned for anyone, with the twists and turns came opportunities for medtech companies to power forward. Innovations came both as a result of the COVID-19 pandemic and perhaps in spite of the challenges brought on by the virus, highlighted by the increased efforts to produce vaccines and testing while […]
Abiomed
First patients treated with Abiomed ECMO tech
Abiomed (NSDQ:ABMD) announced that it treated the first two patients with its Abiomed Breethe OXY-1 compact cardiopulmonary bypass system. Danvers, Mass.-based Abiomed’s extracorporeal membrane oxygenation (ECMO) technology pumps, oxygenates and removes carbon dioxide from blood for patients whose lungs can’t provide sufficient end-organ oxygenation, according to a news release. Breethe OXY-1 is designed to help oxygenate […]
How did medtech companies score on environmental stewardship list?
Medical Design & Outsourcing recently rated the world’s largest medical device companies — the Big 100 — for their sales numbers and R&D spend. Now we can share how some of them scored on an environmental nonprofit’s annual list of companies ranked for their actions on climate change. Not-for-profit organization CDP (Stockholm, Sweden) runs a global disclosure system for […]
Study: ECMO ‘significantly’ improves heart attack patients’ survival
The National Institutes of Health (NIH) is touting a study that found the use of life support improved survival in certain cardiac arrest patients. Published in The Lancet, the study, known as the Advanced Reperfusion Strategies for Refractory Cardiac Arrest (ARREST) trial, used the life support machine called extracorporeal membrane oxygenation ECMO to replicate the […]
Abiomed slides despite beating The Street in Q2
Abiomed (NSDQ:ABMD) shares took a hit today on second-quarter results that beat the consensus forecast. The Danvers, Mass.-based company posted profits of $62.2 million, or $1.36 per share, on sales of $209.8 million for the three months ended Sept. 30, 2020, nearly quadrupling its bottom line on sales growth of 2.3%. Adjusted to exclude one-time items, […]
FDA clears Abiomed compact cardiopulmonary bypass system
Abiomed (NSDQ:ABMD) announced today that FDA has granted a 510(k) clearance for its Breethe OXY-1 system — which among other things could help treat people with severe cases of COVID-19. The Abiomed Breethe OXY-1 system is an all-in-one, compact cardiopulmonary bypass system. It provides cardiopulmonary bypass support for people whose lungs are no longer able to […]
Abiomed touts latest Impella trial results
Abiomed (NSDQ:ABMD) today announced interim results of a study that found high-risk patients had better outcomes after implantation with its Impella CP heart pump. Data from the PROTECT III FDA post-approval study of Impella 2.5 and Impella CP in high-risk percutaneous coronary intervention (PCI) patients showed reduced rates of MACCE — a composite of death, stroke, […]
CMS rate cuts for Abiomed Impella not as bad as expected
CMS will pay 11% less for the tiny Impella heart pump made by Abiomed (NSDQ:ABMD) during the upcoming federal fiscal year — but the reduction is better than the 24% cut originally proposed. For the federal fiscal year ended Sept. 30, 2021, the rate for uni-ventricular Impella percutaneous insertion will be $71,950, down from the previous […]
Medtech stocks help boost S&P rally
Medtech stocks helped the S&P 500 Index reach record highs today amid a bounceback from the lows of the COVID-19 pandemic. Reuters reported that medtech played its part in the record turn of the market, with Abiomed (NSDQ:ABMD), Regeneron Pharmaceuticals (NSDQ:REGN) and West Pharmaceutical Services (NYSE:WST), all of which are involved in developing COVID-19 therapeutics, all rising more […]
MedTech 100 roundup: Another high as stocks tick up
For the third consecutive week, stocks in the medtech industry reached heights not yet seen since the COVID-19 pandemic began. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.65 points at the end of last week (Aug. 7). Overall, medtech stocks saw a 0.72% increase from […]
Abiomed shares slide on Street-beating Q1 results
Abiomed (NSDQ:ABMD) posted first-quarter results today that beat the consensus on Wall Street. The Danvers, Mass.-based company reported profits of $44.6 million, or 98¢ per share, on sales of $164.9 million for the three months ended June 30, for a bottom-line loss of -95% sales loss of -20.6% compared with Q1 2019. Adjusted to exclude one […]
